12.94

4.22% -0.57

After Hours: 13.03 0.09 +0.70%

Mink Therapeutics Inc (INKT)

Overview News Price History Financials Discussions Forecast

Mink Therapeutics Inc stock is traded at $12.94, with a volume of 62,112. It is down -4.22% in the last 24 hours and up +32.85% over the past month. MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.

Previous Close:

$13.51

Open:

$13.6

24h Volume:

62,112

Relative Volume:

0.23

Market Cap:

$64.26M

Revenue:

Net Income/Loss:

$-12.49M

P/E Ratio:

-4.3645

EPS:

-2.9648

Net Cash Flow:

$-5.93M

1W Performance:

+16.05%

1M Performance:

+32.85%

6M Performance:

-12.45%

1Y Performance:

+66.97%

1-Day Range:

$12.47

$13.75

1-Week Range:

$10.90

$13.84

52-Week Range:

$6.34

$76.00

Mink Therapeutics Inc Stock (INKT) Company Profile

Name

Mink Therapeutics Inc

Sector

Healthcare (1112)

Industry

Biotechnology (621)

Phone

212-994-8250

Address

149 FIFTH AVENUE, NEW YORK

Employee

Twitter

Next Earnings Date

2026-03-31

Latest SEC Filings

INKT's Discussions on Twitter

Compare INKT vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
INKT Mink Therapeutics Inc	12.94	67.09M	0	-12.49M	-5.93M	-2.9648
VRTX Vertex Pharmaceuticals Inc	441.70	113.01B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	753.93	79.87B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	840.87	51.51B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	333.39	45.29B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	319.94	34.41B	5.36B	287.73M	924.18M	2.5229

Mink Therapeutics Inc Stock (INKT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-15-25	Upgrade	H.C. Wainwright	Neutral → Buy
Jul-14-25	Downgrade	William Blair	Outperform → Mkt Perform

Mink Therapeutics Inc Stock (INKT) Latest News

Apr 14, 2026

INKT SEC FilingsMink Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan

Apr 14, 2026

The INKT Cell Story: Why Investors Need To Watch MiNK Therapeutics Closely - RTTNews

Apr 14, 2026

Apr 10, 2026

Retail Surge: What is MiNK Therapeutics Incs P E ratio telling us2026 Top Gainers & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn

Apr 10, 2026

Smart Money: Whats the fair value of MiNK Therapeutics Inc stockWeekly Stock Summary & AI Enhanced Trade Execution Alerts - baoquankhu1.vn

Apr 10, 2026

Apr 09, 2026

MiNK Therapeutics (INKT) finance officer reports 222 indirect shares on Form 3 - Stock Titan

Apr 09, 2026

Fed Meeting: What is the target price for MiNK Therapeutics Inc stock2026 Key Highlights & Fast Entry High Yield Tips - baoquankhu1.vn

Apr 09, 2026

Apr 08, 2026

MiNK Therapeutics – Three Weeks. Three Catalysts - Oncodaily

Apr 08, 2026

INKT PE Ratio & Valuation, Is INKT Overvalued - Intellectia AI

Apr 08, 2026

Apr 07, 2026

MiNK Therapeutics clarifies status of potential combination trials and investments By Investing.com - Investing.com

Apr 07, 2026

Apr 05, 2026

(INKT) and the Role of Price-Sensitive Allocations - Stock Traders Daily

Apr 05, 2026

MiNK Therapeutics, Inc. (NASDAQ:INKT) Given Average Recommendation of "Hold" by Brokerages - MarketBeat

Apr 05, 2026

Apr 04, 2026